Title: Cholesteryl ester-transfer protein inhibitors stimulate aldosterone biosynthesis in adipocytes through Nox-dependent processes.
Journal: The Journal of pharmacology and experimental therapeutics20150401
Title: Future of cholesteryl ester transfer protein inhibitors.
Journal: Annual review of medicine20140101
Title: Solubility and stability of dalcetrapib in vehicles and biological media.
Journal: International journal of pharmaceutics20121101
Title: Evidence of a drug-drug interaction linked to inhibition of ester hydrolysis by orlistat.
Journal: Journal of cardiovascular pharmacology20121001
Title: Tangier disease: epidemiology, pathophysiology, and management.
Journal: American journal of cardiovascular drugs : drugs, devices, and other interventions20121001
Title: Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
Journal: Journal of lipid research20120901
Title: Dalcetrapib , a cholesteryl ester transfer protein modulator.
Journal: Expert opinion on investigational drugs20120901
Title: Rationale for cholesteryl ester transfer protein inhibition.
Journal: Current opinion in lipidology20120801
Title: HDL and CETP Inhibition: Will This DEFINE the Future?
Journal: Current treatment options in cardiovascular medicine20120801
Title: Lipid and apoprotein composition of HDL in partial or complete CETP deficiency.
Journal: Current vascular pharmacology20120701
Title: Determination of dalcetrapib by liquid chromatography-tandem mass spectrometry.
Journal: Journal of pharmaceutical and biomedical analysis20120701
Title: Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme.
Journal: European heart journal20120701
Title: An update on the clinical development of dalcetrapib (RO4607381), a cholesteryl ester transfer protein modulator that increases HDL cholesterol levels.
Journal: Future cardiology20120701
Title: Current status of CETP inhibitors in the treatment of hyperlipidemia: an update.
Journal: Current clinical pharmacology20120501
Title: Design, synthesis and structure-activity-relationship of 1,5-tetrahydronaphthyridines as CETP inhibitors.
Journal: Bioorganic & medicinal chemistry letters20120501
Title: Dalcetrapib--restoring belief in modulating CETP as a beneficial mechanism in cardiovascular disease.
Journal: Expert opinion on investigational drugs20120401
Title: Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial.
Journal: European heart journal20120401
Title: Cholesteryl ester transfer protein inhibition and endothelial function: enough with the surrogates.
Journal: European heart journal20120401
Title: No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Journal: International journal of clinical pharmacology and therapeutics20120401
Title: Monitoring Cyp2b10 mRNA expression at cessation of 2-year carcinogenesis bioassay in mouse liver provides evidence for a carcinogenic mechanism devoid of human relevance: the dalcetrapib experience.
Journal: Toxicology and applied pharmacology20120315
Title: Pharmacotherapy. Elevating HDL-cholesterol levels with dalcetrapib is safe.
Journal: Nature reviews. Cardiology20120306
Title: On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Journal: Drugs20120305
Title: Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Journal: American heart journal20120301
Title: CETP inhibition in perspective.
Journal: Atherosclerosis20120201
Title: New horizons for cholesterol ester transfer protein inhibitors.
Journal: Current atherosclerosis reports20120201
Title: Efficacy and safety of dalcetrapib in type 2 diabetes mellitus and/or metabolic syndrome patients, at high cardiovascular disease risk.
Journal: Diabetes, obesity & metabolism20120101
Title: Lipid exchange mechanism of the cholesteryl ester transfer protein clarified by atomistic and coarse-grained simulations.
Journal: PLoS computational biology20120101
Title: Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.
Journal: Nutrition & metabolism20120101
Title: Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
Journal: Vascular health and risk management20120101
Title: Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia.
Journal: Core evidence20120101
Title: Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib.
Journal: Drug design, development and therapy20120101
Title: Lipids, blood pressure, kidney - what was new in 2011?
Journal: Archives of medical science : AMS20111231
Title: [Secondary coronary heart disease prevention. Will CEPT inhibitors be the next breakthrough?].
Journal: MMW Fortschritte der Medizin20111208
Title: Cholesteryl ester transfer protein inhibition in cardiovascular risk management: ongoing trials will end the confusion.
Journal: Cardiovascular therapeutics20111201
Title: Familial hypercholesterolemia: present and future management.
Journal: Current cardiology reports20111201
Title: Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse-phase protein arrays.
Journal: Journal of lipid research20111201
Title: Effect of dalcetrapib, a CETP modulator, on non-cholesterol sterol markers of cholesterol homeostasis in healthy subjects.
Journal: Atherosclerosis20111201
Title: Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
Journal: Trends in pharmacological sciences20111201
Title: Therapy and clinical trials.
Journal: Current opinion in lipidology20111201
Title: Investigational CETP antagonists for hyperlipidemia and atherosclerosis prevention.
Journal: Expert opinion on investigational drugs20111101
Title: Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial.
Journal: Lancet (London, England)20111029
Title: Dalcetrapib: turning the tide for CETP inhibition?
Journal: Lancet (London, England)20111029
Title: Anacetrapib: hope for CETP inhibitors?
Journal: Cardiovascular therapeutics20111001
Title: Coronary artery disease: Dalcetrapib safely raises HDL-cholesterol level in the phase IIb dal-PLAQUE trial.
Journal: Nature reviews. Cardiology20110927
Title: Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
Journal: Current opinion in lipidology20110801
Title: Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography.
Journal: American heart journal20110801
Title: Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.
Journal: Current atherosclerosis reports20110601
Title: Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
Journal: European heart journal20110601
Title: Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
Journal: Clinical therapeutics20110601
Title: [Cholesteryl ester transfer protein inhibition in the management of atherosclerotic cardiovascular disease: second act 'A rebirth of hope'].
Journal: Revista medica de Chile20110601
Title: Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey.
Journal: Xenobiotica; the fate of foreign compounds in biological systems20110501
Title: Learning lessons from Pfizer's $800 million failure.
Journal: Nature reviews. Drug discovery20110301
Title: Rationale and design of dal-VESSEL: a study to assess the safety and efficacy of dalcetrapib on endothelial function using brachial artery flow-mediated vasodilatation.
Journal: Current medical research and opinion20110101
Title: Anacetrapib and dalcetrapib: two novel cholesteryl ester transfer protein inhibitors.
Journal: The Annals of pharmacotherapy20110101
Title: [Novel therapy for atherosclerosis and inflammatory vascular disease].
Journal: Nihon rinsho. Japanese journal of clinical medicine20110101
Title: Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: a randomized, double-blind, placebo-controlled, phase I study.
Journal: Clinical drug investigation20110101
Title: Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
Journal: Drug design, development and therapy20110101
Title: Where are we heading with noninvasive clinical vascular physiology? Why and how should we assess endothelial function?
Journal: Cardiology research and practice20110101
Title: Emerging therapeutic strategies to enhance HDL function.
Journal: Lipids in health and disease20110101
Title: Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport.
Journal: Journal of lipid research20101201
Title: Lack of clinically relevant drug-drug interactions when dalcetrapib is co-administered with ezetimibe.
Journal: British journal of clinical pharmacology20101201
Title: Good news for 'good' cholesterol.
Journal: Nature20101118
Title: Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions.
Journal: Journal of clinical pharmacology20101001
Title: No clinically relevant drug-drug interactions when dalcetrapib is co-administered with atorvastatin.
Journal: Expert opinion on investigational drugs20101001
Title: Emerging drugs for hyperlipidemia.
Journal: Expert opinion on emerging drugs20100901
Title: Biochemical characterization of cholesteryl ester transfer protein inhibitors.
Journal: Journal of lipid research20100901
Title: Mechanisms underlying off-target effects of the cholesteryl ester transfer protein inhibitor torcetrapib involve L-type calcium channels.
Journal: Journal of hypertension20100801
Title: Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
Journal: European journal of clinical pharmacology20100801
Title: Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?
Journal: Journal of hypertension20100801
Title: Dissociating HDL cholesterol from cardiovascular risk.
Journal: Lancet (London, England)20100731
Title: Dalcetrapib: a review of Phase II data.
Journal: Expert opinion on investigational drugs20100601
Title: High-density lipoprotein-mediated anti-atherosclerotic and endothelial-protective effects: a potential novel therapeutic target in cardiovascular disease.
Journal: Current pharmaceutical design20100501
Title: Dalcetrapib: JTT 705; JTT-705; R 1658; R1658; RG1658; RO 4607381; RO4607381.
Journal: Drugs in R&D20100501
Title: MARCO, a macrophage scavenger receptor highly expressed in rodents, mediates dalcetrapib-induced uptake of lipids by rat and mouse macrophages.
Journal: Toxicology in vitro : an international journal published in association with BIBRA20100401
Title: [HDL and CETP in atherogenesis].
Journal: Deutsche medizinische Wochenschrift (1946)20100201
Title: Functional assessment of HDL: Moving beyond static measures for risk assessment.
Journal: Cardiovascular drugs and therapy20100201
Title: Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
Journal: European heart journal20100201
Title: Mulling over the odds of CETP inhibition.
Journal: European heart journal20100201
Title: Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.
Journal: European heart journal20100101
Title: Insights from recent meta-analysis: role of high-density lipoprotein cholesterol in reducing cardiovascular events and rates of atherosclerotic disease progression.
Journal: Journal of clinical lipidology20100101
Title: Update on CETP inhibition.
Journal: Journal of clinical lipidology20100101
Title: Low high-density lipoprotein cholesterol: current status and future strategies for management.
Journal: Vascular health and risk management20100101
Title: High density lipoproteins-based therapies for cardiovascular disease.
Journal: Journal of cardiovascular disease research20100101
Title: Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in rats.
Journal: British journal of pharmacology20091201
Title: Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
Journal: American heart journal20091201
Title: The pharmacology and off-target effects of some cholesterol ester transfer protein inhibitors.
Journal: The American journal of cardiology20091116
Title: Mechanism of inhibition defines CETP activity: a mathematical model for CETP in vitro.
Journal: Journal of lipid research20091101
Title: Cholesteryl ester transfer protein inhibitors as high-density lipoprotein raising agents.
Journal: Expert opinion on therapeutic patents20090901
Title: Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
Journal: Current opinion in investigational drugs (London, England : 2000)20090901
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20090901
Title: Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation.
Journal: The Journal of biological chemistry20090717
Title: The end of the road for CETP inhibitors after torcetrapib?
Journal: Current opinion in cardiology20090701
Title: Safety and tolerability of dalcetrapib.
Journal: The American journal of cardiology20090701
Title: In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
Journal: Current medical research and opinion20090401
Title: A single-center, open-label, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib.
Journal: Clinical therapeutics20090301
Title: Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia.
Journal: Thrombosis research20090101
Title: JTT-705: is there still future for a CETP inhibitor after torcetrapib?
Journal: Expert opinion on investigational drugs20081001
Title: Gateways to clinical trials.
Journal: Methods and findings in experimental and clinical pharmacology20080501
Title: Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended?
Journal: Expert opinion on investigational drugs20080401
Title: Is raising HDL a futile strategy for atheroprotection?
Journal: Nature reviews. Drug discovery20080201
Title: HDL metabolism and CETP inhibition.
Journal: Cardiology in review20080101
Title: Gateways to clinical trials. July-August 2008.
Journal: Methods and findings in experimental and clinical pharmacology20080101
Title: The role of CETP inhibition in dyslipidemia.
Journal: Current atherosclerosis reports20070801
Title: The biology and chemistry of hyperlipidemia.
Journal: Bioorganic & medicinal chemistry20070715
Title: Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
Journal: Clinica chimica acta; international journal of clinical chemistry20070101
Title: Inhibition of CETP as a novel therapeutic strategy for reducing the risk of atherosclerotic disease.
Journal: European heart journal20070101
Title: Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
Journal: Pharmacology & therapeutics20060901
Title: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction.
Journal: Current opinion in lipidology20060801
Title: Are human CETP mutations and CETP-inhibiting drugs a good or a bad deal?
Journal: Journal of molecular medicine (Berlin, Germany)20060801
Title: Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors.
Journal: Current opinion in pharmacology20060401
Title: Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
Journal: Journal of the American College of Cardiology20060207
Title: Increasing high-density lipoprotein cholesterol through cholesteryl Ester transfer protein inhibition: a next step in the fight against cardiovascular disease?
Journal: Current drug targets. Cardiovascular & haematological disorders20051201
Title: JTT-705 blocks cell proliferation and angiogenesis through p38 kinase/p27(kip1) and Ras/p21(waf1) pathways.
Journal: Atherosclerosis20051001
Title: Consequences of cholesteryl ester transfer protein inhibition in patients with familial hypoalphalipoproteinemia.
Journal: Arteriosclerosis, thrombosis, and vascular biology20050901
Title: Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies.
Journal: Current opinion in cardiology20050701
Title: Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
Journal: The American journal of cardiology20050501
Title: Role of CETP inhibitors in the treatment of dyslipidemia.
Journal: Current opinion in lipidology20041201
Title: Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits.
Journal: Arteriosclerosis, thrombosis, and vascular biology20041001
Title: S-(2-(acylamino)phenyl) 2,2-dimethylpropanethioates as CETP inhibitors.
Journal: Bioorganic & medicinal chemistry letters20040517
Title: JTT-705. Japan Tobacco.
Journal: Current opinion in investigational drugs (London, England : 2000)20040301
Title: Inhibition of cholesteryl ester transfer protein increases serum apolipoprotein (apo) A-I levels by increasing the synthesis of apo A-I in rabbits.
Journal: Atherosclerosis20040201
Title: Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells.
Journal: American journal of physiology. Endocrinology and metabolism20030601
Title: Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals.
Journal: European journal of pharmacology20030411
Title: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis.
Journal: Arteriosclerosis, thrombosis, and vascular biology20030201
Title: Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia.
Journal: Clinical science (London, England : 1979)20021201
Title: The Yin and Yang of cholesteryl ester transfer protein and atherosclerosis.
Journal: Clinical science (London, England : 1979)20021201
Title: Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
Journal: Circulation20020507
Title: Effect of HDL, from Japanese white rabbit administered a new cholesteryl ester transfer protein inhibitor JTT-705, on cholesteryl ester accumulation induced by acetylated low density lipoprotein in J774 macrophage.
Journal: Atherosclerosis20020501
Title: [CETP inhibitor].
Journal: Nihon rinsho. Japanese journal of clinical medicine20010301
Title: Niesor EJ, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res. 2010, 51(12), 3443-3454.
Title: Shinkai H, et al. J Med Chem. bis(2-(Acylamino)phenyl) disulfides, 2-(acylamino)benzenethiols, and S-(2-(acylamino)phenyl) alkanethioates as novel inhibitors of cholesteryl ester transfer protein. 2000, 43(19), 3566-3572.
Title: Huang Z, et al. Dual effects on HDL metabolism by cholesteryl ester transfer protein inhibition in HepG2 cells. Am J Physiol Endocrinol Metab. 2003, 284(6), E1210-E1219.
